当前位置: X-MOL 学术Sci. Adv. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Revisiting the PD-1 pathway.
Science Advances ( IF 13.6 ) Pub Date : 2020-09-18 , DOI: 10.1126/sciadv.abd2712
Nikolaos Patsoukis 1, 2 , Qi Wang 1, 2 , Laura Strauss 1, 2 , Vassiliki A Boussiotis 1, 2
Affiliation  

Programmed Death-1 (PD-1; CD279) is an inhibitory receptor induced in activated T cells. PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also compromises anti-tumor immunity. Blocking antibodies against PD-1 or its ligands have revolutionized cancer immunotherapy. However, only a fraction of patients develop durable antitumor responses. Clinical outcomes have reached a plateau without substantial advances by combinatorial approaches. Thus, great interest has recently emerged to investigate, in depth, the mechanisms by which the PD-1 pathway transmits inhibitory signals with the goal to identify molecular targets for improvement of the therapeutic success. These efforts have revealed unpredictable dimensions of the pathway and uncovered novel mechanisms involved in PD-1 and PD-L1 regulation and function. Here, we provide an overview of the recent advances on the mechanistic aspects of the PD-1 pathway and discuss the implications of these new discoveries and the gaps that remain to be filled.



中文翻译:

重新审视 PD-1 通路。

Programmed Death-1 (PD-1; CD279) 是一种在活化的 T 细胞中诱导的抑制性受体。PD-1 与其配体 PD-L1 和 PD-L2 的结合可维持外周耐受性,但也会影响抗肿瘤免疫。阻断针对 PD-1 或​​其配体的抗体已经彻底改变了癌症免疫疗法。然而,只有一小部分患者会产生持久的抗肿瘤反应。在没有通过组合方法取得实质性进展的情况下,临床结果已达到稳定水平。因此,最近出现了极大的兴趣来深入研究 PD-1 通路传递抑制信号的机制,目的是确定分子靶点以提高治疗成功率。这些努力揭示了该通路的不可预测的维度,并揭示了参与 PD-1 和 PD-L1 调节和功能的新机制。这里,

更新日期:2020-09-20
down
wechat
bug